Phase 3 Eczema trials recruiting now

All Eczema trials, every phase

Other phases for Eczema

Phase 3 Eczema trials

• A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
  NCT07355075 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
  NCT06807281 · Phase: Phase 3 · Ages: 2 Years to 11 Years · Sex: All (male and female) · 41 locations
• A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
  NCT07711418 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 13 locations
• A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
  NCT07690371 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 19 locations
• A Study of Lebrikizumab in Adults With Nummular Eczema
  NCT07542483 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
  NCT07309055 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 2 locations
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
  NCT06389136 · Phase: Phase 3 · Ages: 18 Years to 63 Years · Sex: All (male and female) · 128 locations
• A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
  NCT06807268 · Phase: Phase 3 · Ages: 6 Years to 11 Years · Sex: All (male and female) · 46 locations
• A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
  NCT06461897 · Phase: Phase 3 · Ages: 2 Years to 11 Years · Sex: All (male and female) · 150 locations
• A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
  NCT06587685 · Phase: Phase 3 · Ages: 12 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
  NCT06241118 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 150 locations
• A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
  NCT07765888 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 3 locations
• A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
  NCT06311682 · Phase: Phase 3 · Ages: 6 Months to 11 Years · Sex: All (male and female) · 72 locations
• Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
  NCT06880276 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
  NCT06239311 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children
  NCT04419584 · Phase: Phase 2, Phase 3 · Ages: 4 Years to 17 Years · Sex: All (male and female) · 1 location
• Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
  NCT07042126 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 3 locations
• Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
  NCT07370909 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma
  NCT06560255 · Phase: Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · 2 locations
• Herbal Ointment in Treating Atopic Dermatitis Topically
  NCT06850311 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
  NCT06775860 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 62 locations
• Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
  NCT06723080 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis
  NCT07592585 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 1 location
• VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma
  NCT06570889 · Phase: Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · 2 locations

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.